Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Estudy Site

Neither a doctor nor a teaching hospital

Research payments

$928,854

325 payments

Through program year 2023, Estudy Site is reported as receiving $928,854 in research payments, across 325 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $227 2
2022 Research $9,465 2
2021 Research $64,693 155
2020 Research $254,150 36
2019 Research $600,318 130

Breakdown

Who paid Research payments · program years 2019–2023
  1. GlaxoSmithKline, LLC. $371,680 30 payments
  2. AstraZeneca UK Limited $178,967 7 payments
  3. Allergan Inc. $137,268 41 payments
  4. Gilead Sciences, Inc. $93,015 30 payments
  5. Novo Nordisk AS $73,097 201 payments
  6. AstraZeneca Pharmaceuticals LP $25,451 3 payments
  7. Novartis Pharmaceuticals Corporation $24,357 3 payments
  8. Merck Sharp & Dohme Corporation $13,040 4 payments
  9. ViiV Healthcare Company $8,446 2 payments
  10. Janssen Research & Development, LLC $3,374 3 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Phase Iia Single-Center, Open-Label Study Evaluating the Pharmacokin $266,332 5 payments
  2. A Phase I Randomized, Single blind, Placebo controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Multiple Ascending Subcutaneous Dose Administration in Subjects with Diabetes Type 2 $162,163 4 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $110,493 32 payments
  4. A Phase 3 Study to Compare the Efficacy and Safety of Gepotidacin With $105,326 24 payments
  5. Nn9931-4296 $53,148 50 payments
  6. A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (Ljn452) & Licogliflozin (Lik066) Combination Therapy, Compared to Each Monotherapy, for Treatment of Adult Patients With Nonalco $20,200 2 payments
  7. A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) $19,470 1 payment
  8. AZD2693, Cardiovascular, Renal and Metabolism $16,803 3 payments
  9. Nn1250-4252 $15,132 5 payments
  10. A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $14,896 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record